I-Estrogen Crash: Ukwelapha Ukunqamuka Kwesikhashana Kwangaphambi Kokuqala
Unyaka ngamunye izinkulungwane zabesifazane abaneminyaka engama-15 no-44 zihlangabezana ne-Estrogen Crash, ukuwa kwehla ngokungazelelwe kumazinga e-estrogen eshiya abesifazane ekuqedeni kokuya esikhathini sokuqala. Nakuba ukuphuma esikhathini eside kubonakala njengenkinga kwabesifazane asebekhulile, abesifazane abaningi abasebasha abathola ukukhulelwa esikhathini sokuqala bazithola bengakulungele izinguquko ezingalindelekile ezenzekayo.
I-Estrogen Crash kwenzeka uma kokubili ama-ovaries wesifazane esuswa noma ngokuyeka kungazelelwe ukusebenza. Uma kwenzeka lokhu umzimba uyeka ukukhiqiza i- estrogen .
"Ngokwemvelo, abesifazane besifazane abanesifo samadoda asehla kancane kancane emazingeni e-estrogen esikhathini esingaphezu kweminyaka emibili kuya kweyishumi. Ngokuphambene, ukukhishwa kwe-estrogen yabesifazane abasebasha abaye bahlinzwa esikhathini sokuhlinzwa noma ukuhluleka kwe-ovarian kunqunywa ngokushesha," kusho uDkt. Lila Nachtigall, MD, uMqondisi I-Division of Wellness Division e-New York University Medical School. "Umphumela ukufika okungazelelwe nokushesha kwezibonakaliso ze-vasomotor: ukushisa okushisayo, ukujula ebusuku , ukuphazamiseka kokulala okuhambisana nokulala okwesifazane."
Abesifazane abangaphezu kwesigamu sesigidi bahamba ngokweqile minyaka yonke e-United States futhi ingxenye engaphezu kwengu-50 ye-hysterectomies ihlanganisa i-oophorectomy yamazwe amabili- ukususwa kokubili ama-ovari. Abesifazane abangaphezu kwezingu-20 abangena ngaphansi kwe-oophorectomy ephakathi kwama-40 bangaphansi kuka-40. Cishe owesifazane kwabayishumi uzokwenyuka ukuhluleka kwe-ovarian ngaphambi kweminyaka engama-40.
Isikhathi sokunqamuka kwe-Arsenal vs. Estrogen Crash
Abesifazane abahlangabezana nokuya esikhathini esingakapheli isikhathi eside bavame ukubhekana nokuya esikhathini eside kwabesifazane abahlangabezana nokuya esikhathini esijwayelekile uma bekhulile. Esimeni semvelo, amazinga e-estrogen ayancipha kancane kancane phakathi neminyaka emibili kuya kwengu-10, kuyilapho abesifazane besifazane besifazane behlinzwa ngokukhahlazeka kwe-estrogen.
"Ngokuvamile, owesifazane ohamba ngokuya esikhathini esizayo ngeke ahlangabezane nezimpawu ze-vasomotor njalo," kusho uDkt. Lila Nachtigall. "Kuyinto eqhubekayo kakhulu. Isiguli singase sibe nenyanga eyodwa embi lapha noma lapho. Kodwa uma kwenzeka i-oophorectomy ephakathi, imiphumela yilapho iziguli ezincane kakhulu futhi ezincane, ikakhulukazi, zingabhekana nokuzizwa kanzima."
Emzimbeni kaDkt. Nachtigall, abesifazane abangamaphesenti angu-100 abahlinzeka ngamaphilisi angama-vasomotor futhi abangu-90% kulaba besifazane babhekana nezibonakaliso ezinzima ezaba neminyaka eyi-8.5. Ngokuphambene, nakuba abesifazane abangamaphesenti angama-85% abesilisa abanesifo somzimba basuke bezwa ukushisa okushisa, cishe kuphela u-15% wabhekana nezibonakaliso ezinzima. Ngesikhathi abesifazane befinyelela esikhathini sokuya esikhathini esingokwemvelo, cishe amaphesenti angama-43 abika ngokulinganisela izimpawu ezinzima ezithinta emva kweminyaka engaba ngu-2.
Abesifazane abathola ukuphuma komama ngokuzumayo emva kokuphuma kwe-oophorectomy ephakathi kwamanye amazwe bavame ukugula ngokushesha ngemva kokuhlinzwa ukugwinya amaphilisi. Izikhathi eziningi odokotela banquma istigen e-estrogen eboshwe esikhumbeni futhi ikhulula i-estrogen ngesikhumba ukuya egazini ngezinsuku. Inzuzo ye-estrogen patch yilezi zidingo ezikhishwe isikhathi.
Okuncane kunazo zonke kulezi zimpawu eziyi-Vivelle-Dot. Umthamo we -00 mg / wosuku ubukhulu besitembu sokuthunyelwa kanye no-75% amancane kunama-estrogen avches.
It igqoke esiswini esingaphansi lapho inikeza i-estradiol ngokusebenzisa isikhumba sesikhumba esidluliselwa emgodleni wegazi. I-Estradiol yi- estrogen eyinhloko eyenziwa ngama-ovari. I-Vivelle-Dot ishintshwe kabili ngeviki futhi idlula ngamanzi, ukubhukuda, neminye imisebenzi yansuku zonke ngaphandle kokuphuma. I-punch inikeza ukukhululeka ekukhanyeni okushisayo, ukujula ebusuku, nezinye izimpawu ze-Estrogen Crash noma ukuyeka esikhathini sokuzalwa kwemvelo.
I-Vivelle-Dot itholakala kwamanye amandla amathathu okulinganisa; .0375, .075, no-.1 mg / ngosuku. Imiphumela emibi kakhulu ebikwe yilezi zikhanda ezincane kanye nokucasula isikhumba esincane.Izivalo ezimbi ezingezansi ze-Vivelle (R) * (i-estradiol transdermal system) kanye ne-placebo, ngokulandelana, zibandakanya ikhanda (36% vs. 30%), ithenda lebele (4.9% vs 1.1%), nokugcina amanzi (3.8% vs.2.2%).
Ezinye iziguli ezithatha i-Vivelle-Dot (TM) 0.0375 mg / ngosuku zingase zizwe ukuqala kokubambezeleka kokusebenza kahle.
Abesifazane abathile akufanele basebenzise i-estrogens. Lokhu kufaka phakathi abesifazane abathintekayo noma abasolwa ukukhulelwa, ukuphuma kwegazi okungavamile okungavamile, umdlavuza webele, neoplasia esekelwe yi-estrogen, i-thrombophlebitis esebenzayo noma izifo ze-thromboembolic, noma umlando oqoshiwe wale mibandela. U-Estrogens kuye kwabikwa ukuthi kwandisa ingozi ye-endometrial carcinoma kumama-postmenopausal.
U-W. Neil Jones, uMqondisi Omkhulu Wokuthengisa Nokuthengisa kwe-Noven Pharmaceuticals, Inc. uthi abezindaba kanye nomphakathi wokunakekelwa kwezempilo kufanele basize abesifazane abasebasha ukuba baqonde imiphumela engenzeka ye-Estrogen Crash ukuze bakwazi ukwenza isinqumo esifanele uma bezithola bebhekene ukuphuma esikhathini sokuqala.
I-Vivelle-Dot (TM) idayiswa yi-Novogyne Pharmaceuticals, ukusebenzisana phakathi kwe-Novartis Pharmaceuticals Corporation yase-East Hanover, eNew Jersey, ne-Noven Pharmaceuticals, Inc. yaseMiami, eFlorida.
* Ukwakhiwa kwangempela (Vivelle) (R) okuvivinywe ekuvivinyweni kwemitholampilo kuye kwabuyekezwa ukunciphisa ubukhulu be-patch kanye nokubunjwa okubukeziwe (i-Vivelle-Dot) (TM) kuboniswe ukuthi kufanelana ne-formulation original.
Umthombo wolwazi: PRNewswire / NEWSdesk